Researchers are exploring the potential of empagliflozin and intermittent fasting to reduce the risk of heart damage caused by certain cancer treatments. Some studies suggest that intermittent fasting, such as the 5:2 diet, may also have benefits for people with type 2 diabetes. The approach is being investigated as a possible strategy to mitigate cardiotoxicity and potentially offer benefits for diabetes management.